PRECLINICAL DEVELOPMENT OF A ROMIDEPSIN NANOPARTICLE DEMONSTRATES SUPERIOR TOLERABILITY AND EFFICACY IN MODELS OF HUMAN T-CELL LYMPHOMA AND LARGE GRANULAR LYMPHOCYTE LEUKEMIA
Ipsita Pal, Anuradha Illendula, Andrea Joyner…·Owen A. O’Connor
Author
University of Virginia Medical CenterORCID 0000-0003-4981-1691Unclaimed ORCID profile · follow to get notified of new preprints
5 papers
Recent·Most cited
Ipsita Pal, Anuradha Illendula, Andrea Joyner…·Owen A. O’Connor
Johnson Ung, Su‐Fern Tan, Jeremy J.P. Shaw…·Thomas P. Loughran
This study shows that inhibiting acid ceramidase (AC) enhances venetoclax's effectiveness in venetoclax-resistant AML by inducing a cytotoxic integrated stress response.
James T. Hagen, McLane M. Montgomery, Raphael Taiwo Aruleba…·Kelsey H. Fisher‐Wellman
This study identifies a bioenergetic mechanism in AML cells where mitochondria consume ATP to resist chemotherapy, offering a target for improving treatment.
B. Bishal Paudel, Su‐Fern Tan, Todd E. Fox…·Thomas P. Loughran
This study identifies two sphingolipidomic subtypes in AML, with one subtype associated with poor clinical outcomes and high-risk features.
Weiling Li, Lei Yang, Robert S. Harris…·Mary L. Poss
The paper analyzes LGL leukemia patient genomes to detect retrovirus integration sites but finds no new retroviruses, instead identifying polymorphic HERV-K provirus sites more prevalent in LGL patients.